Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in four clinical programs: systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Employee Rating

5.0More
TypePublic
HQNorwood, US
Founded2009
Size (employees)25 (est)
Websitecorbuspharma.com
Corbus Pharmaceuticals was founded in 2009 and is headquartered in Norwood, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Corbus Pharmaceuticals

Yuval Cohen

Yuval Cohen

Chief Executive Officer, Director
Mark A. Tepper

Mark A. Tepper

President & Chief Scientific Officer
Barbara White

Barbara White

Chief Medical Officer
Robert Discordia

Robert Discordia

Vice President, Pharmaceutical Development & Manufacturing
Ross Lobell

Ross Lobell

Vice President, Regulatory Affairs
Show more

Corbus Pharmaceuticals Office Locations

Corbus Pharmaceuticals has an office in Norwood
Norwood, US (HQ)
103 100 River Ridge Dr
Show all (1)
Report incorrect company information

Corbus Pharmaceuticals Financials and Metrics

Corbus Pharmaceuticals Revenue

USD

Net income (Q3, 2018)

(14.6m)

EBIT (Q3, 2018)

(14.9m)

Market capitalization (14-Dec-2018)

372.6m

Closing stock price (14-Dec-2018)

6.5

Cash (30-Sep-2018)

55.7m
Corbus Pharmaceuticals's current market capitalization is $372.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

3.6m6.5m9.0m

R&D expense

5.9m15.4m26.0m

Operating expense total

9.5m21.9m35.0m

EBIT

(8.9m)(20.0m)(32.6m)
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

General and administrative expense

969.1k790.6k1.1m1.0m1.8m2.4m1.9m2.1m3.1m3.0m3.2m

R&D expense

1.7m1.6m2.2m3.6m4.3m6.4m5.8m5.6m9.8m10.3m12.8m

Operating expense total

2.7m2.4m3.3m4.6m6.1m8.7m7.6m7.8m12.8m13.2m16.0m

EBIT

(2.6m)(2.3m)(2.9m)(4.2m)(5.3m)(7.5m)(7.3m)(7.0m)(11.9m)(12.4m)(14.9m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

12.3m15.0m62.5m

Current Assets

12.7m17.4m65.5m

PP&E

124.1k435.3k1.4m

Total Assets

12.9m17.9m67.0m
Annual
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.9m)(20.0m)(32.4m)

Depreciation and Amortization

43.9k87.7k255.7k

Accounts Payable

972.2k1.9m(885.8k)

Cash From Operating Activities

(4.6m)(13.6m)(27.8m)
Quarterly
USDQ3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(1.3m)(4.1m)(6.4m)(2.9m)(7.1m)(12.4m)(7.5m)(14.8m)(21.7m)(11.7m)(23.8m)(38.4m)

Depreciation and Amortization

5.0k11.5k26.2k17.3k37.2k57.7k31.5k64.5k191.1k81.9k206.3k338.7k

Accounts Payable

308.7k925.1k383.8k642.2k1.4m191.0589.4k517.7k1.2m628.2k3.7m

Cash From Operating Activities

(1.0m)(1.3m)(3.7m)(2.5m)(5.0m)(8.2m)(6.6m)(12.4m)(18.7m)(1.6m)(7.2m)(16.0m)
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information

Corbus Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information

Corbus Pharmaceuticals News and Updates

Corbus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

Norwood, MA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry leading pipeline focused on treating inflammatory and fibrotic diseases through the endocannabinoid system (“…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in November

– Jefferies 2018 London Healthcare Conference presentation with live audio webcast on Thursday, November 15 at 4:40 p.m. GMT –

Corbus Pharmaceuticals Expands Target Indications by Adding More Than 600 Compounds Focused on the Endocannabinoid System from Jenrin Discovery; Includes CRB-4001 with Planned NIH-Supported Phase 2 Study

Norwood, MA, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”) announced today that it has licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 compounds targeting the endoca…

Corbus Pharmaceuticals Receives Orphan Designation for Lenabasum for the Treatment of Dermatomyositis in the European Union

– Dermatomyositis is a rare chronic systemic autoimmune disease characterized by inflammation of muscles and skin

Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting

Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented

Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference

Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory an…
Show more
Report incorrect company information

Corbus Pharmaceuticals Blogs

Corbus Pharmaceuticals to Announce Third Quarter 2018 Operational and Financial Results on November 8, 2018

- Company to host conference call and webcast on Nov. 8th at 8:30 AM ET - Norwood, MA, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company with the industry’s leading pipeline focused on …

Corbus Pharmaceuticals Presents Lenabasum Long-Term Open-Label Clinical Data Showing Maintenance of Favorable Safety Profile and Further Improvement in Multiple Efficacy Endpoints in Systemic Sclerosis and Dermatomyositis Phase 2 Studies

Lenabasum is a first-in-class novel, synthetic oral cannabinoid designed to treat rare, serious autoimmune diseases Favorable safety and tolerability profiles maintained with long-term chronic dosing Further improvement in key efficacy outcomes shows strength and durability of therapeutic effect M…

Corbus Pharmaceuticals Presents Data on Impact of Lenabasum on Inflammation of Airway Macrophages from Cystic Fibrosis Lungs at the 2018 North American Cystic Fibrosis Conference

Study demonstrates that lenabasum decreases inflammatory biomarkers and increases pro-resolving mediators in airway macrophages from cystic fibrosis patients Cystic fibrosis is a life-threatening rare genetic disease that affects ~30,000 patients in the U.S. and ~70,000 patients worldwide Chr…

Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034

Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid system Intellectual property around pipeline targeting endocannabinoid system now covers lenabasum and CRB-4001 Lenabasum is in late-stage clinical studies in three orph…

Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October

– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat and live audio webcast on Tuesday, October 2nd at 3:00 PM ET – Norwood, MA , Sept. 26, 2018 (G…

Corbus Pharmaceuticals to Commence Phase 3 Study of Lenabasum for the Treatment of Rare Autoimmune Disease Dermatomyositis

Phase 3 study follows positive 16-weeks Phase 2 data and further improvement in efficacy outcomes with open-label extension dosing at six months 12-month 150 subject study with ACR/EULAR 2016 Total Improvement Score in myositis as primary efficacy outcome Approximately 80,000 dermatomyositis patie…
Show more

Corbus Pharmaceuticals Company Life and Culture

Report incorrect company information

Corbus Pharmaceuticals Frequently Asked Questions

  • When was Corbus Pharmaceuticals founded?

    Corbus Pharmaceuticals was founded in 2009.

  • Who are Corbus Pharmaceuticals key executives?

    Corbus Pharmaceuticals's key executives are Yuval Cohen, Mark A. Tepper and Barbara White.

  • How many employees does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 25 employees.

  • Who are Corbus Pharmaceuticals competitors?

    Competitors of Corbus Pharmaceuticals include Rigel Pharmaceuticals, Novartis and GlaxoSmithKline.

  • Where is Corbus Pharmaceuticals headquarters?

    Corbus Pharmaceuticals headquarters is located at 103 100 River Ridge Dr, Norwood.

  • Where are Corbus Pharmaceuticals offices?

    Corbus Pharmaceuticals has an office in Norwood.

  • How many offices does Corbus Pharmaceuticals have?

    Corbus Pharmaceuticals has 1 office.